Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study

被引:6
|
作者
Li, Rui [1 ]
Lu, Danli [1 ]
Li, Hao [2 ]
Wang, Yuge [1 ]
Shu, Yaqing [1 ]
Chang, Yanyu [1 ]
Sun, Xiaobo [1 ]
Lu, Zhengqi [1 ]
Qiu, Wei [1 ,3 ]
Yang, Zhi [2 ]
机构
[1] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 3, Guangzhou, Peoples R China
[2] Maoming Peoples Hosp, Dept Neurol, 101 Weimin Rd, Maoming, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Neurol, Multiple Sclerosis Ctr, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuromyelitis optica spectrum disorders; Vomiting; Area postrema; Clinical outcomes; AQP4 antibody titers;
D O I
10.1186/s12883-021-02059-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Early stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, the clinical characteristics and long-term outcomes of these patients remain unknown. We sought to analyze the clinical characteristics, imaging features, and long-term outcomes of NMOSD with non-opticospinal manifestations as initial symptoms. Methods We retrospectively included relevant patients from our center. Clinical, demographic, magnetic resonance imaging, treatment, and outcome data were compared according to the non-opticospinal vs. opticospinal initial symptoms. Results We identified 43 (9.13 %) patients with non-opticospinal initial symptoms among 471 patients with NMOSD. Of these, 88.37 % developed optic neuritis/myelitis during an average follow-up period of 6.33 years. All the non-opticospinal symptoms were brain/brainstem symptoms. Most of the symptoms and associated brain lesions were reversible. These patients had a younger onset age (P < 0.001), lower serum aquaporin-4 (AQP4) antibody titers (P = 0.030), and a lower Expanded Disability Status Scale (EDSS) score at onset (P < 0.001) and follow-up (P = 0.041) than NMOSD patients with opticospinal initial symptoms. In addition, EDSS scores reached 3.0 (indicating moderate disability) later than in patients with opticospinal initial symptoms (P = 0.028). Conclusions Patients with NMOSD with non-opticospinal initial symptoms have a younger onset age, lower serum AQP4 antibody titers, and better clinical outcomes.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study
    Rui Li
    Danli Lu
    Hao Li
    Yuge Wang
    Yaqing Shu
    Yanyu Chang
    Xiaobo Sun
    Zhengqi Lu
    Wei Qiu
    Zhi Yang
    BMC Neurology, 21
  • [2] Neuromyelitis optica spectrum disorder with acute brainstem manifestations as initial symptoms
    Li, Zhen
    Yang, Minggang
    Pan, Yang
    Fang, Qi
    HELIYON, 2024, 10 (12)
  • [3] Long-term therapy and symptomatic treatment of neuromyelitis optica spectrum disorders
    Vachova, M.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 : S62 - S67
  • [4] Long-term effect of cyclosporine A in the prophylaxis of neuromyelitis optica spectrum disorders
    Kageyama, Takashi
    Miyamoto, Katsuichi
    Ozaki, Akihiko
    Komori, Mika
    Okunomiya, Taro
    Kambe, Daisuke
    Suenaga, Toshihiko
    Kusunoki, Susumu
    Matsumoto, Sadayuki
    Takahashi, Ryosuke
    Kondo, Takayuki
    NEUROLOGY, 2016, 86
  • [5] Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
    Galvao Ribeiro Gomes, Ana Beatriz Ayroza
    Pitombeira, Milena Sales
    Sato, Douglas Kazutoshi
    Callegaro, Dagoberto
    Apostolos-Pereira, Samira Luisa
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (03) : 229 - 232
  • [6] Long-term effect of cyclosporine A in the prophylaxis of neuromyelitis optica spectrum disorders
    Kageyama, Takashi
    Miyamoto, Katsuichi
    Ozaki, Akihiko
    Komori, Mika
    Okunomiya, Taro
    Kambe, Daisuke
    Suenaga, Toshihiko
    Kusunoki, Susumu
    Matsumoto, Sadayuki
    Takahashi, Ryosuke
    Kondo, Takayuki
    NEUROLOGY, 2016, 86
  • [7] Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in caucasian patients
    Radaelli, M.
    Sangalli, F.
    Moiola, L.
    Rodegher, M.
    Colombo, B.
    Esposito, F.
    Fazio, R.
    Martinelli, V.
    Comi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 351 - 351
  • [8] Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
    Radaelli, M.
    Moiola, L.
    Sangalli, F.
    Esposito, F.
    Barcella, V.
    Ferre, L.
    Rodegher, M.
    Colombo, B.
    Fazio, R.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (04) : 511 - 519
  • [9] Advances in the long-term treatment of neuromyelitis optica spectrum disorder
    Anderson, Monique
    Levy, Michael
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2024, 16
  • [10] Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
    Jagtap, Sujit Abajirao
    Mandliya, Alok
    Sarada, C.
    Nair, M. D.
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2015, 6 (03) : 331 - 335